| 前收市價 | 21.11 |
| 開市 | 21.09 |
| 買盤 | 20.21 x 200 |
| 賣出價 | 20.26 x 200 |
| 今日波幅 | 20.04 - 21.12 |
| 52 週波幅 | 12.32 - 32.10 |
| 成交量 | |
| 平均成交量 | 801,769 |
| 市值 | 874.863M |
| Beta 值 (5 年，每月) | -0.37 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.32 |
| 業績公佈日 | 2024年8月01日 - 2024年8月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 2012年12月13日 |
| 1 年預測目標價 | 無 |
InvestorPlaceStock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech Stocks
Investing in the biotech sphere isn’t for the faint of heart, and you should steer clear of the biotech stocks to avoid. That’s because biotech stocks tend to experience wild swings in developments, such as clinical trial outcomes or drug approvals. Unsurprisingly, the SPDR S&P Biotech ETF had shed roughly 40% in value over the past three years, when the broader market gained 22%. Hence, investors pondering over biotech stocks to avoid them will always remain relevant. Moreover, they’re probably
InvestorPlaceExit Now! 3 Biotech Stocks to Sell in February 2024
The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges. Moreover, despite forecasts pointing to a potential rebound in 2024, the biotech industry is struggling to adapt post-pandemic. For many biotech firms, securing private funding and launching successful IPOs remains a daunting tas
Motley FoolIs There Any Hope for Cassava Sciences Stock?
Battered by controversy, this company will need to show real results to prosper.
